10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Shares of RNAi therapeutics company Alnylam Pharmaceuticals fell 2.37% to $80.01 by close of trading on Monday, after the company revealed that it would not aim for accelerated approval of givosiran. 16 October 2018
Two pivotal Phase III placebo-controlled trials evaluating Dupixent (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps (CRSwNP) met all primary and secondary endpoints. 16 October 2018
Swedish firm Medivir has announced that Uli Hacksell will replace Christine Lind as chief executive, with immediate effect, just 18 months after she took up the position. 16 October 2018
Combinations involving checkpoint therapies are starting to be used as the standard of care in certain metastatic cancer types, such as Merck & Co’s Keytruda (pembrolizumab) with chemotherapy in advanced squamous non-small cell lung cancer. 16 October 2018
Cell therapy specialist SQZ Biotechnologies has expanded a collaboration with Swiss giant Roche to bring forward candidates based on antigen presenting cells (APCs). 15 October 2018
New Jersey’s Merck & Co has reportedly backed away from taking a biosimilar follow-on product to market in the USA, despite already having tentative approval to do so from the US Food and Drug Administration. 15 October 2018
Germany’s Probiodrug (AMS: PBD) announced to the stock market that a cumulative loss of more than half of the nominal share capital of the company has been incurred, due to operating losses resulting from ordinary business operations. 15 October 2018
Shares in West Coast, USA-based oncology specialist Immune Design have fallen more than a third since it announced an unfavorable early analysis of a Phase II trial of its cancer vaccine candidate CMB305. 15 October 2018
Top-line results from the Phase III CheckMate-331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin (where approved), in patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy, did not meet its primary endpoint of overall survival (OS) versus chemotherapy. 12 October 2018
US cost-effectiveness watchdog the Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of therapies for long-term prophylaxis against hereditary angioedema (HAE) attacks. 12 October 2018
Privately-owned Austrian biotech Themis Bioscience has bought in additional assets from a German research group to expand its immunomodulation platform into oncology. 12 October 2018
The USA’s MEI Pharma has lined up with China’s BeiGene on a clinical collaboration to evaluate the safety and efficacy of MEI’s ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene’s zanubrutinib, an investigational BTK inhibitor, for the treatment of patients with B-cell malignancies. 12 October 2018
A post-hoc analysis of the SUSTAIN study of crizanlizumab, Novartis’ humanized anti-P-selectin monoclonal antibody being investigated for the treatment of sickle cell disease (SCD), have been presented ahead of an expected US filing in 2019. 11 October 2018
The firm that calls itself the leading oncology company in Japan strengthened its position on Wednesday with the approval of its breast cancer drug in a new indication in the Asian country. 11 October 2018
Israel-based Compugen saw its share leap 18% in pre-market trading on news of a collaboration with a US pharma major on COM701, an investigational anti-PVRIG antibody. 11 October 2018
The US Food and Drug Administration has lifted the clinical hold placed in May this year and accepted the Investigational New Drug application (IND) for CTX001 for the treatment of sickle cell disease (SCD). 11 October 2018
Initial public offerings (IPOs) are often seen as attractive by business owners in the life sciences or biotech field, writes Alan Wovsaniker, a partner with Lowenstein Sandler, in an Expert View column on the topic. 11 October 2018
German biotech Evotec today revealed that it will receive a $6 million payment from Celgene following Celgene's decision to expand the collaboration to include additional cell lines. 11 October 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024